<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01839786</url>
  </required_header>
  <id_info>
    <org_study_id>DOP14</org_study_id>
    <nct_id>NCT01839786</nct_id>
  </id_info>
  <brief_title>Evaluation of Lung Doppler Signals in Pulmonary Hypertension</brief_title>
  <official_title>Evaluation of Lung Doppler Signals in Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Echosense Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Echosense Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the lung Doppler signals in patients with pulmonary&#xD;
      hypertension that undergo (prospective arm) or underwent (retrospective arm) right heart&#xD;
      catheterization (RHC) in order to assess whether this non-invasive tool could be used in&#xD;
      pulmonary hypertension diagnosis and monitoring.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL SUMMARY&#xD;
&#xD;
      Title: Evaluation of lung Doppler signals (LDS) in pulmonary hypertension (PHTN) Device:&#xD;
      SONARA/tek transcranial Doppler (TCD) system Study Objectives: To evaluate the LDS in&#xD;
      patients with PHTN that undergo (prospective arm) or underwent (retrospective arm) right&#xD;
      heart catheterization (RHC) in order to assess whether these signals can be used in pulmonary&#xD;
      hypertension diagnosis and monitoring.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      Two study arms:&#xD;
&#xD;
        1. Prospective arm to measure LDS during right heart catheterization in patients undergoing&#xD;
           the procedure for evaluation of PHTN.&#xD;
&#xD;
        2. Retrospective arm to measure LDS in patients in whom previous RHC confirmed the presence&#xD;
           of PHTN.&#xD;
&#xD;
      Recruitment target: Prospective arm: 50 patients during 18 months. Retrospective arm: 50&#xD;
      patients during 18 months.&#xD;
&#xD;
      Study Population:&#xD;
&#xD;
        1. Patients suspected of PHTN by echocardiogram, who are scheduled to undergo RHC&#xD;
           (prospective arm)&#xD;
&#xD;
        2. Patients who underwent RHC in the past and were diagnosed with PHTN (retrospective arm)&#xD;
&#xD;
      Study endpoint:&#xD;
&#xD;
        1. Comparison of pulmonary blood pressures at rest, following vasodilator medication and&#xD;
           following upper extremities exercise as measured by RHC and by the LDS during the&#xD;
           Valsalva maneuver.&#xD;
&#xD;
        2. Determining LDS characteristics of PHTN patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Find specific features that characterize lung signals of PHTN patients in comparison to control patients</measure>
    <time_frame>18 months</time_frame>
    <description>The outcomes will be elaborate by statistical analysis of whole group data</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">45</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>PHTN patients</arm_group_label>
    <description>2. Patients who underwent RHC in the past and were diagnosed with PHTN (retrospective arm)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suspected of PHTN&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Prospective arm:&#xD;
&#xD;
               -  Man or woman aged over 18.&#xD;
&#xD;
               -  With suspicion or diagnosis of pulmonary hypertension.&#xD;
&#xD;
               -  Scheduled to undergo right heart catheterization&#xD;
&#xD;
               -  Able and willing to give informed consent.&#xD;
&#xD;
          2. Retrospective arm:&#xD;
&#xD;
               -  Man or woman aged over 18.&#xD;
&#xD;
               -  With diagnosis of pulmonary hypertension confirmed by right heart catheterization&#xD;
                  in the past.&#xD;
&#xD;
               -  Able and willing to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Both arms:&#xD;
&#xD;
               -  Minor (aged &lt; 18).&#xD;
&#xD;
               -  People unable or unwilling to give informed consent.&#xD;
&#xD;
               -  Hemodynamically unstable patients.&#xD;
&#xD;
               -  Pregnant women.&#xD;
&#xD;
          2. Prospective arm only:&#xD;
&#xD;
               -  Patients with contra-indication to right heart catheterization.&#xD;
&#xD;
               -  Patients incapable of performing a Valsalva maneuver.&#xD;
&#xD;
               -  Patients with recent myocardial infarction, high degree AV block, severe aortic&#xD;
                  stenosis or glaucoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Issahar Ben-Dov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical center, Pulmonary institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheba Medical Center, Pulmonology department</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 18, 2013</study_first_submitted>
  <study_first_submitted_qc>April 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2013</study_first_posted>
  <last_update_submitted>March 19, 2017</last_update_submitted>
  <last_update_submitted_qc>March 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>Doppler</keyword>
  <keyword>Valsalva</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

